Table 3 Potential targets for NETs inhibition in different disease
Agent/Inhibitor | Target/Function | Disease/Pathology | Subject of research | Reference |
|---|---|---|---|---|
DNase I | Degrading formed NETs | Diabetic wound healing | Diabetic mouse | [120] |
| Â | Liver IRI | Liver IRI mouse | [121] | |
| Â | lung injury/ARDS | MRSA-infected mouse | [122] | |
| Â | SLE | Serum of SLE patients | ||
| Â | Scar formation | Mouse model of laminectomy | [67] | |
| Â | Cystic fibrosis | Cystic fibrosis patients | ||
| Â | Colorectal cancer | MC38-bearing mouse | [127] | |
| Â | Hepatocellular carcinoma | Hepa1-6 or HuH7 bearing mouse | ||
| Â | Breast cancer | SCP28-bearing mouse | [129] | |
| Â | Pancreatic cancer | Panc02-bearing mouse | [19] | |
rhDNase I | Degrading formed NETs | COVID-19 Infection | Patients in Phase I clinical trial | NCT04409925 |
GSK484 | Inhibitor of PAD4 | Renal IRI | Renal IRI mouse | [130] |
| Â | Lung injury | SAH mouse | [131] | |
| Â | Hepatocellular carcinoma | Hepa1-6 bearing mouse | [132] | |
| Â | Breast cancer | 4T1-bearing mice | ||
Cl-amidine | Inhibitor of PAD4 | Mastitis | LPS-induced mouse mastitis | [133] |
Endometritis | LPS-induced rat endometritis | [134] | ||
BMS-P5 | Inhibitor of PAD4 | Multiple myeloma | DP42-bearing mouse | [135] |
Sivelestat | Inhibitor of NE | Ovarian cancer | Human neutrophils | [136] |
Breast cancer | SCP28-bearing mouse | [129] | ||
GW311616 | Inhibitor of NE | Diffuse large B-cell lymphoma | A20-bearing mouse | [21] |
Inflammatory responses | Human neutrophils | [137] | ||
AZD5904 | Inhibitor of MPO | Multiple organ dysfunction in sepsis | Human neutrophils | [138] |
Reparixin | CXCR1/2 inhibitor | solid malignancies | Tumor-bearing mice | [28] |
Danirixin | CXCR2 antagonist | COPD | Patients in Phase II clinical trial | NCT03250689 |
Metformin | Inhibiting NADPH oxidase activity | SLE | Proof-of-Concept Trial | [139] |